The purpose of the present study was to perform a BPH risk factor analysis in men, relating the prostate gland volume to components of the metabolic syndrome and to identify clues to the etiology of BPH.
Introduction
The etiology of benign prostatic hyperplasia (BPH) is unknown. 1, 2 Several etiologic factors for BPH have been proposed. Most interest has been focused on the steroid hormones, especially testosterone and oestrogen and their metabolites. 1±10 However, up to now, few data have linked BPH to any aberration in steroid hormones.
A clinical observation that diabetic and obese men had larger prostate glands than men without these conditions initiated this present study. If this clinical observation could be veri®ed, it would mean that diabetes and obesity are risk factors for BPH. Identi®cation of such risk factors could give important information concerning etiologic factors in BPH.
Diabetes mellitus has previously been suggested to be a risk factor for BPH, based on a ®nding of a higher ageadjusted prevalence of diabetes mellitus among men subjected to prostatectomy than in the general male population. 11 Daniell 12 found increased specimen weights with increasing obesity in men subjected to transurethral resection of the prostate. However, Sidney et al 13 reported that surgery for BPH was performed less frequently among overweight men and Glynn et al 14 reported that obese men were less likely than lean men to have a clinical diagnosis of BPH based on symptoms and digital rectal examination.
The need of a prostate operation, however, is poorly correlated with the extent of BPH.
15±17 It is also obvious that the resection weight and data based on symptoms and digital rectal examination provide poor estimates of the prostate gland volume. In recent years, it has become possible to measure the prostate gland volume with great accuracy using the ultrasound technique. 18, 19 Diabetes mellitus and obesity are common conditions which are components of the metabolic syndrome. 20 Other facets of this syndrome are atherosclerosis, hypertension and dyslipidemia. 20 These diseases of the metabolic syndrome have been described as one entity with insulin resistance and a secondary hyperinsulinemia as common denominators.
20±22
The present study was designed as a risk factor analysis of BPH in which the prostate gland volume, as measured with ultrasound, was related to components of the metabolic syndrome including atherosclerosis, noninsulin-dependent diabetes mellitus (NIDDM), treated hypertension, obesity, dyslipidemia and hyperinsulinemia.
Patients and methods
One hundred and ®fty-eight patients referred to the Urological Section, Department of Surgery, Varberg Hospital, Varberg, Sweden, with lower urinary tract symptoms were included consecutively in this study. Varberg Hospital has a strictly de®ned catchment area with a permanent population of 135 000 people. The Swedish health care system is organized in such a way that a great majority of men living in this area are referred to Varberg Hospital for medical care, including urologic problems. Most of these men were investigated merely because of lower urinary tract symptoms and needed no treatment. A few of these men were later on subjected to medical or surgical treatment because of BPH. The median age was 70 y (range 45±82 y). Men with a known malignant disease, including prostatic cancer, men with a signi®cant body weight change ( AE 10 kg) during the last 10 y, men on ®nasteride and a-adrenergic blocking medication and men subjected to a previous transurethral resection of the prostate with unknown resection weight were excluded.
The diagnosis metabolic syndrome, including atherosclerosis, treated hypertension and diabetes mellitus, was provided by the patient's medical history. Atherosclerotic disease includes coronary artery disease, cerebrovascular disease and peripheral arterial insuf®ciency. Coronary artery disease includes symptoms of effort angina and a history of myocardial infarction. Cerebrovascular disease is de®ned as a history of stroke or a transitory ischemic attack (TIA) documented by the patient ®le. Patients with a history of arterial aneurysm, intermittent claudication, rest pain or peripheral gangrene caused by arterial insuf®ciencyÐwhether subjected to surgery or notÐwere de®ned as patients with peripheral arterial insuf®ciency. A patient was said to have had hypertension if this condition was pharmacologically treated and non-insulin-dependent diabetes mellitus (NIDDM) if this diagnosis was provided by the patient's medical history.
Data on blood pressure, waist and hip measure, body height and body weight were collected and body mass index (BMI, kg per m 2 ) and waist/hip ratio (WHR) were calculated. The prostate gland was examined using digital rectal examination and ultrasound equipment (B & K Medical 3535). If prostatic cancer was suspected, several ultrasound-guided core biopsies of the prostate gland were collected for histopathological examination. The prostate gland volume was determined by means of ultrasound using the ellipsoid method. At the calculation of the annual BPH growth rate, it was estimated that the prostate gland volume was 20 ml when the patient was 20 y old. 23 Blood samples were drawn from overnight-fasting patients. Serum for determination of insulin was separated within one hour of sampling and stored at À20 C until assayed. Fresh serum was analysed for total cholesterol, HDL-cholesterol, triglycerides, uric acid and alanine aminotransferas (ALAT, EC 2.6.1.2.).
Serum insulin was measured with a radioimmunoassay kit, Insulin RIA 100, from Pharmacia Diagnostics, Uppsala, Sweden, using a human insulin standard. Total cholesterol, HDL-cholesterol, triglycerides, uric acid and ALAT were analysed on a Synchrone CX7 instrument from Beckman Instruments Inc, Brea, California, USA, with reagents from the same supplier. HDL-cholesterol was measured in the supernatant after precipitation with dextran sulphate and magnesium chloride. LDL-cholesterol was calculated using the Friedewald formula.
Since most variables in this report were not normally distributed, we preferred to use non-parametric statistics, namely the median value, the Spearman correlation coef®cient and the Mann±Whitney U-test in the calculations. When performing linear multiple regression analyses, the variables were transformed into logarithms.
Results
The values of the prostate gland volume correlated signi®cantly with the calculated annual BPH growth rate (r s 0.93; P`0.0001). The patients with NIDDM had signi®cantly larger prostate gland volumes and a faster annual BPH growth rate than men without NIDDM (Table 1) . Table 2 shows that men treated for hypertension had a larger prostate gland volume and a faster BPH growth rate than men who had not been treated for this disorder. There was a signi®cant correlation coef®cient between the systolic blood pressure and the prostate gland volume (r s 0.17; P 0.03). Table 3 shows that obese men (waist measure ! 95 cm) had a larger prostate gland volume and a faster annual BPH growth rate than lean men (waist measure`95 cm). There was a signi®cant correlation coef®cient between waist measures and the prostate gland volumes (r s 0.34; P`0.0001) and the annual BPH growth rates (r s 0.31; P`0.001). Statistical testing with hip measure, WHR and BMI as alternative tests of obesity also gave results which were statistically signi®cant.
The prostate gland volume and the annual BPH growth rate in men with low HDL-cholesterol (`1.18 mmol/l) and high HDL-cholesterol ( ! 1.18 mmol/l) are given in Table 4 . Men with low HDL-cholesterol had a larger prostate gland volume and a faster annual BPH growth rate than men with high HDL-cholesterol. There was a signi®cant negative correlation coef®cient between the HDL-cholesterol level and the prostate gland volume (r s À0.22; P 0.009). Table 5 shows that men with high fasting insulin ( ! 9 mU/ml) had a larger prostate gland volume and a faster annual BPH growth rate than men with low fasting insulin (`9 mU/ml). The fasting insulin values correlated signi®cantly with the prostate gland volumes and the annual BPH growth rates (r s 0.38; P`0.0001; r s 0.36; P`0.0001, respectively).
When the results from men with one or several components of the metabolic syndrome (NIDDM, hypertension, obesity (waist measure ! 95 cm), high insulin level ( ! 9 mU/ml) or low HDL-cholesterol level (`1.18 mmol/l)) were compiled and compared with results from men without any of these conditions, the prostate gland volume was found to be larger and the annual BPH growth rate faster in the men with one or several components of the metabolic syndrome ( Table 6 ).
The cholesterol, LDL-cholesterol, triglyceride, uric acid and ALAT levels were not statistically signi®cantly related to the prostate gland volume or the calculated annual BPH growth rate.
As indicated in Tables 1±6, there were differences in median ages between the groups tested. Therefore, the relationship between NIDDM and the prostate gland volume, between hypertension and the prostate gland volume, between obesity and the prostate gland volume, between HDL-cholesterol and the prostate gland volume, between insulin and the prostate gland volume and between the metabolic syndrome and the prostate gland volume was analysed in multivariate analyses allowing for age differences. The effects of NIDDM, treated hypertension, obesity, HDL cholesterol level, insulin level and the metabolic syndrome on the prostate gland volumes were still signi®cant (Tables 1±6). The age effects in these analyses were also signi®cant.
All factors shown to correlate signi®cantly with the prostate gland volume (age, presence of NIDDM and hypertension, waist measure, HDL-cholesterol and insulin levels) were used as covariates in a step-wise multiple regression analysis. Age, waist measure and insulin level had statistically signi®cant effects on the prostate gland volume (P 0.02, P 0.0046 and P 0.0007, respectively). The degrees of explained variance for these factors were 3, 6 and 8%, respectively.
The prostate gland volume and BPH growth rate in men with atherosclerotic disease including coronary artery disease, cerebrovascular disease and peripheral arterial insuf®ciency did not differ from the prostate gland volume and BPH growth rate in men without these diseases (data not given).
Discussion
The present data con®rm the clinical observation that men suffering from diabetes mellitus and obesity have a larger prostate gland volume than men without these conditions. Moreover, men with other facets of the metabolic syndrome such as treated hypertension, high fasting insulin levels and low HDL-cholesterol levels also had a more pronounced prostate gland enlargement. The validity of these observations is strengthened by the statistically signi®cant correlations between the prostate gland volume on the one hand and systolic blood pressure, four different expressions of obesity, fasting insulin level and HDL-cholesterol levels on the other. These ®ndings taken together show that NIDDM, treated hypertension, obesity, high fasting insulin levels and low HDL-cholesterol levels constitute risk factors for the development of BPH.
At the age of approximately 70 y, the prostate adenomas of diabetic and obese men are 2.3 and 2.0 times larger than the adenomas of men not suffering from these conditions. The corresponding value for men with one or more of the conditions NIDDM, hypertension, obesity, high insulin and low HDL-cholesterol levels compared with men without these conditions is 3.4. In fact, men without signs of the metabolic syndrome had a prostate gland volume of 28.5 ml at the age of 68 y, namely a prostate adenoma growth of 8.5 ml in 48 y since the age of 20. The corresponding growth of prostate adenomas in men with evidence of the metabolic syndrome is 29 ml in 50 y. It is obvious from these data that there is a link between BPH and several components of the metabolic syndrome. In the clinical setting, this means that any doctor presented to a patient with BPH should consider the possible presence of NIDDM, hypertension, obesity, high insulin or low HDL-cholesterol levels in that patient. Conversely, in patients with these conditions, the possibility of a clinically important BPH should be kept in mind, as the prostate gland volume has been shown to correlate positively to the severity of the lower urinary tract symptom and negatively to the peak urinary¯ow rate. 24 The metabolic syndrome has been described as one entity characterized by a defect in the insulin-mediated glucose uptake.
20±22 This primary metabolic abnormality is mainly localized to the muscle and adipose tissue and the liver of these patients, leading to an insulin resistance and a secondary hyperinsulinemia. 25 Thus, the results of the present study point to the possibility that BPH patients may have the same primary metabolic abnormality of a defective insulin-mediated glucose uptake and secondary hyperinsulinemia as patients with the metabolic syndrome.
This conclusion is supported by the following observations. The calculated annual BPH growth rate was increased by 49, 17, 36, 31 and 28% in men with NIDDM, treated hypertension, obesity, a low HDL-cholesterol and high fasting insulin level, respectively. It is apparent from these data that NIDDM and obesity are the two strongest risk factors and hypertension the weakest risk factor for the development of BPH of the conditions studied. These ®ndings are in line with the data of wholebody glucose uptake assessed by the euglycemic insulinclamp technique reported by DeFronzo and Ferrannini. 20 The defects in insulin-mediated glucose metabolism in NIDDM and obese patients were greater than the corresponing defect in hypertensive patients. Therefore, the diagnoses with the most pronounced defects of insulinmediated glucose uptake in their study were the diagnoses with the fastest BPH growth rate in the present report. These ®ndings may suggest that different facets of the metabolic syndrome are linked to the development of BPH in relation to the extent of the defect in the wholebody glucose uptake.
Our ®nding that men suffering from NIDDM, hypertension, obesity and low HDL-cholesterol levels had larger prostate glands than men without these disorders suggests the possibility that hyperinsulinemia is related to the development of BPH as all these conditions are associated with hyperinsulinemia. 20±25 This conclusion is supported by the ®nding that men with high fasting insulin levels had larger prostate glands than men with low fasting insulin. Moreover, there was a strong correlation between fasting insulin and the prostate gland volume. All these ®ndings support the notion that insulin levels might be causally related to the development of BPH.
This hypothesis is also supported by the following ®ndings. In bivariate statistics, age, presence of NIDDM and hypertension, waist measure, HDL-cholesterol and insulin level were factors which signi®cantly were related to the prostate gland volume. However, in a multivariate analysis using these factors as covariates, only age, waist measure and insulin level reached statistical signi®cance. In this analysis the insulin level, statistically, had the most pronounced effect on the prostate gland volume of all covariates tested. It may be argued that the fasting plasma insulin could explain only 8% of the variance of the prostate gland volume. However, it must be realized that the prostate gland volume at the age of approximately 70 y is the result of a process which has gone on for 40±50 y. The plasma insulin value available in the present report, on the other hand, re¯ects the insulin level one of the mornings at the end of this period.
It may also be argued that the prostate gland volume measured with ultrasound in the present report does not necessarily re¯ect the volume of BPH, as the determination gives a value of the total prostate gland volume and not only the volume of the prostate adenomas. However, according to Berry et al 23 the normal prostate gland reaches 20 or À6 gm(ml) in men between 21 and 30 y old and this weight remains essentially constant with increasing age unless BPH develops. Moreover, the morphological examination in this study, using digital rectal examination and ultrasound, has ruled out other known conditions capable of affecting the total prostate gland volume, such as prostate cancer and cysts. Thus, the total prostate gland volume À20 ml used as a measure of BPH in the present report should re¯ect the BPH volume.
Based on extensive BPH research, McNeal 26 has presented a hypothesis that there may be two phases in the development of BPH. The initial phase is stromal hypertrophy and formation of individual small nodules arising from local tissue in¯uences. In accordance with McNeal's hypothesis, the second development phase involves a synchronized enlargement of existing nodules as a result of a systemic endocrine abnormality. It is possible that hyperinsulinemia might be this systemic endocrine abnormality.
The main new concept emerging from this report is that BPH might be a facet of the metabolic syndrome with a defective insulin-mediated glucose uptake and a secondary hyperinsulinemia as possible etiologic factors. If this is true, it might be possible with methods available today to develop effective preventive and therapeutic strategies which may prevent the progression of the disease and reduce the need for surgery.
It has not escaped our attention that another interesting consequence of this new concept is that the well-known bene®cial effect of alpha receptor blockers for urinary obstruction in BPH patients might be explained. It has been demonstrated that insulin has a stimulating effect on the ventromedial hypothalamic nucleus regulating the sympathetic nervous system. 27 Induced hyperinsulinemia has been shown to increase the levels of catecholamines in plasma and tissues. 28 Hyperinsulinemia has also been shown to increase the impulse¯ow in peripheral sympathetic nerves. 28, 29 Thus, it seems reasonable to believe that BPH-patients with elevated insulin levels in accordance with our ®ndings might have an increased sympathetic activity and therefore might react favourably to a-receptor blocking medication.
Another speculative consequence of this new concept is that a-receptor blockers, in addition to having a symptomatic and bene®cial effect on urinary obstruction in BPH patients, also might slow down the development of BPH, as it is well established that a-receptor blockers increase the insulin sensitivity and decrease insulin levels.
30±33
However, the present report is based on a consecutive series of patients who have been referred to our hospital with lower urinary tract symptoms. It cannot be excluded that this referral procedure has introduced some bias. Consequently, another study, based on a representative group of men from our local catchment area, is now in progress.
